Allogene therapeutics initiates pivotal phase 2 trial investigating cemacabtagene ansegedleucel (cema-cel), an allogeneic car t product, as part of first line treatment for patients with large b-cell lymphoma (lbcl) likely to relapse

South san francisco, calif. and boulder, colo., june 20, 2024 (globe newswire) -- allogene therapeutics inc. (nasdaq: allo), a clinical-stage biotechnology company pioneering the development of allogeneic car t (allocar t™) products, and foresight diagnostics (foresight), a leader in ultra-sensitive liquid biopsy-based minimal residual disease (mrd) detection, today announced the initiation of the pivotal phase 2 alpha3 trial evaluating the use of cemacabtagene ansegedleucel (cema-cel) as part of the first line (1l) treatment regimen for newly diagnosed lbcl patients who are likely to relapse after standard 1l treatment and need further therapy.
CAR Ratings Summary
CAR Quant Ranking